ArticleFrontiers in public health2026
Clinical spectrum and factors associated with Brucella epididymo-orchitis among male patients in a high-endemic region of Northwest China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: BEO is a clinically important but often underrecognized localized manifestation of brucellosis in male patients, particularly in high-endemic pastoral regions. However, large-scale data describing its clinical spectrum and associated factors remain limited. This study aimed to characterize the epidemiological, clinical, and laboratory features of BEO among hospitalized male brucellosis patients in Northwest China and to explore clinical and laboratory factors associated with BEO. Methods: This retrospective cross-sectional study was conducted at the regional infectious disease hospital of Ningxia Hui Autonomous Region from January 2021 to December 2023. Male inpatients aged 16 years or older with laboratory-confirmed brucellosis were included. Patients were classified into BEO and non-BEO groups. Demographic, clinical, and laboratory data were extracted from medical records. Univariable analyses were performed to compare the two groups, and multivariable logistic regression was used to identify factors associated with BEO. Results: A total of 1,188 hospitalized male brucellosis patients were included, of whom 72 had clinically recognized and imaging-confirmed BEO, accounting for 6.06% of the study population. In univariable analyses, fatigue, lumbago, positive blood culture, platelet count, white blood cell count, ESR, and symptom duration differed between the BEO and non-BEO groups. In the multivariable model, fatigue (OR = 0.43, 95% CI: 0.23-0.81, Conclusion: In this study, BEO was identified in 6.06% of hospitalized male brucellosis patients, and was associated with lower frequencies of fatigue and lumbago, higher white blood cell count, and positive blood culture. These findings suggest that BEO may represent a distinct localized clinical phenotype rather than a simple extension of systemic or osteoarticular disease. The observed associations should not be interpreted as causal predictors. Prospective multicenter studies with standardized screening, detailed exposure assessment, and longitudinal follow-up are needed to clarify the true burden, mechanisms, and long-term outcomes of BEO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.